-
Mashup Score: 7Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024 - 20 hour(s) ago
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024 - 8 day(s) ago
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Obinutuzumab and Liso-Cel Revisions to CLL/SLL @NCCN Guidelines Mark Most Notable Changes of 2024 @Matt_Cortese @roswellpark #lymsm #leusm https://t.co/y5Zd8WaCe6
-
-
Mashup Score: 1Secondary Malignancies After CAR T: How Big is the Risk? - 7 month(s) ago
Binod Dhakal, MD, MS, discusses the potential risk of secondary cancers like lymphoma and leukemia sometimes seen with chimeric antigen receptor T-cell therapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Binod Dhakal, MD, MS, (@bhemato) discusses the potential risk of secondary cancers like lymphoma & leukemia sometimes seen with CAR T-cell therapies. #lymsm #leusm | @MCWCancerCenter https://t.co/nBOHyfAwlG
-
-
Mashup Score: 4
Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Dr Kenderian on the FDA Approval of Liso-Cel in Relapsed/Refractory CLL/SLL @kenderian_ss @MayoClinic @us_fda #lymsm #leusm https://t.co/2FFQoKzG6g
-
-
Mashup Score: 2Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL - 9 month(s) ago
Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL @SanRaffaeleMI #lymsm #leusm https://t.co/CwHPN7lx1d
-
-
Mashup Score: 2Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL - 9 month(s) ago
Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL @SanRaffaeleMI #lymsm #leusm https://t.co/CwHPN7lx1d
-
-
Mashup Score: 1FDA Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL - 10 month(s) ago
The FDA has granted fast track designation to the novel BTK degrader NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
.@us_fda Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL #lymsm #leusm https://t.co/TSFAARJwNz
-
-
Mashup Score: 1FDA Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL - 10 month(s) ago
The FDA has granted fast track designation to the novel BTK degrader NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
.@us_fda Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL #lymsm #leusm https://t.co/TSFAARJwNz
-
-
Mashup Score: 1FDA Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL - 10 month(s) ago
The FDA has granted fast track designation to the novel BTK degrader NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
.@us_fda Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL #lymsm #leusm https://t.co/TSFAARJwNz
-
-
Mashup Score: 1FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL - 10 month(s) ago
The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
.@us_fda Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL #lymsm #leusm https://t.co/4YHqES6kjE
-
Obinutuzumab and Liso-Cel Revisions to CLL/SLL @NCCN Guidelines Mark Most Notable Changes of 2024 @Matt_Cortese @roswellpark #lymsm #leusm https://t.co/y5Zd8WaCe6